The Type 1 (EGFR-related) Family of Growth Factor Receptors and Their Ligands

Overview

Journal Prog Growth Factor Res

Specialties Biochemistry
Biotechnology

Date 1992 Jan 1

PMID 1355372

Citations 55

Authors

S A Prigent

N R Lemoine

Affiliations

Soon will be listed here.

Abstract

This review considers the biology of the type 1 growth factor receptor family which is increasingly recognised as important in the control of normal cell proliferation and in the pathogenesis of human cancer. The family currently comprises three closely related members: the epidermal growth factor (EGF) receptor, c-erbB-2 and c-erbB-3, all of which show abnormalities of expression in various human tumours. The family of factors related to EGF has also expanded recently and now includes transforming growth factor alpha, heparin-binding EGF, amphiregulin, cripto and heregulin, as well as several other potential ligands for the c-erbB2-2 receptor. The involvement of these receptors and growth factors in human cancer has implications for the design of novel forms of therapy for cancer, and we review recent advances and future avenues for investigation.

Citing Articles

A Comparative Study on Therapeutic Efficacy of Autologous Platelet-rich Plasma, Autologous Platelet-rich Fibrin Matrix, Recombinant Human Epidermal Growth Factor, and Collagen Particles in Nonhealing Leg Ulcers.

Gehlawat T, Karia U, Shah S, Vyas H, Parghi M, Doshi Y J Cutan Aesthet Surg. 2023; 16(2):121-127.

PMID: 37554680 PMC: 10405547. DOI: 10.4103/JCAS.JCAS_116_22.

Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule.

Popa X, Garcia B, Fuentes K, Huerta V, Alvarez K, Viada C Oncoimmunology. 2020; 9(1):1762465.

PMID: 32923124 PMC: 7458606. DOI: 10.1080/2162402X.2020.1762465.

Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes.

Yang Z, Tam K Int J Biol Sci. 2018; 14(2):204-216.

PMID: 29483838 PMC: 5821041. DOI: 10.7150/ijbs.22955.

Ginkgol C17:1 inhibits tumor growth by blunting the EGF- PI3K/Akt signaling pathway.

Li Y, Liu J, Yang X, Dong Y, Liu Y, Chen M J Biomed Res. 2017; 31(3):232-239.

PMID: 28808215 PMC: 5460611. DOI: 10.7555/JBR.31.20160039.

p85α promotes nucleolin transcription and subsequently enhances EGFR mRNA stability and EGF-induced malignant cellular transformation.

Xie Q, Guo X, Gu J, Zhang L, Jin H, Huang H Oncotarget. 2016; 7(13):16636-49.

PMID: 26918608 PMC: 4941340. DOI: 10.18632/oncotarget.7674.